Response by Singfer and Defreyne to Letter Regarding Article, "Unruptured Brain Arteriovenous Malformations: Primary ONYX Embolization in ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-Eligible Patients"

Affiliations

¹ Faculty of Medicine and Health Sciences, Ghent University Hospital, Belgium.
² Department of Interventional Neuroradiology, Ghent University Hospital, Belgium.

Comment

Uri Singfer et al. Stroke. 2018 Mar.

. 2018 Mar;49(3):e137.

doi: 10.1161/STROKEAHA.118.020396. Epub 2018 Feb 13.

¹ Faculty of Medicine and Health Sciences, Ghent University Hospital, Belgium.
² Department of Interventional Neuroradiology, Ghent University Hospital, Belgium.

No abstract available

Comment on

Unruptured Brain Arteriovenous Malformations: Primary ONYX Embolization in ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-Eligible Patients.
Singfer U, Hemelsoet D, Vanlangenhove P, Martens F, Verbeke L, Van Roost D, Defreyne L. Singfer U, et al. Stroke. 2017 Dec;48(12):3393-3396. doi: 10.1161/STROKEAHA.117.018605. Epub 2017 Nov 7. Stroke. 2017. PMID: 29114088 Clinical Trial.
Letter by Liu and Chen Regarding Article, "Unruptured Brain Arteriovenous Malformations: Primary ONYX Embolization in ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-Eligible Patients".
Liu F, Chen J. Liu F, et al. Stroke. 2018 Mar;49(3):e136. doi: 10.1161/STROKEAHA.117.020347. Epub 2018 Feb 13. Stroke. 2018. PMID: 29440473 No abstract available.